<DOC>
	<DOCNO>NCT00003859</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether undergo surgery plus radiation therapy effective without chemotherapy primitive neuroectodermal tumor CNS . PURPOSE : Randomized phase III trial compare effectiveness surgery plus radiation therapy without chemotherapy treat patient primitive neuroectodermal tumor CNS .</brief_summary>
	<brief_title>Surgery Plus Radiation Therapy With Without Chemotherapy Treating Children With Primitive Neuroectodermal Tumors CNS</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether chemotherapy utilize carboplatin , vincristine , cyclophosphamide , etoposide improve prognosis child primitive neuroectodermal tumor central nervous system give surgery radiotherapy . II . Assess prospective factor may determine ultimate prognosis patient population . III . Determine quality survival patient treatment regimen . OUTLINE : This randomize study . Patients undergo surgical removal primary tumor . Following surgery , patient randomize receive radiotherapy alone ( arm I ) chemotherapy follow radiotherapy ( arm II ) . Arm I : Patients begin receive radiotherapy soon possible surgery , within 28 day . Radiotherapy administer 5 time week 6 week . Arm II : Within 28 day surgery , patient receive vincristine IV day 1 , 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 . Carboplatin IV administer 1 hour day 1 , 2 , 42 , 43 . Etoposide IV administer 1 hour day 1-3 , 21-23 , 42-44 , 63-65 . Cyclophosphamide IV administer 4 hour day 21 63 . As soon possible chemotherapy , patient receive radiotherapy arm I . Quality life assess every 3 month first year annually thereafter . Patients follow every 6 week first year , every 3 month second year , every 4 month third year , every 6 month thereafter . PROJECTED ACCRUAL : A total 230 patient ( 115 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primitive neuroectodermal tumor central nervous system No metastatic disease within outside central nervous system Must survive 1 week follow surgery Postoperative CT scan myelogram require PATIENT CHARACTERISTICS : Age : 3 16 Performance status : Not specify Life expectancy : Not specify Hematopoietic : No concurrent hematological disorder Hepatic : Not specify Renal : Renal dysfunction allow Other : No prior history malignant disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
</DOC>